^
Association details:
| Biomarker: | 12-CK gene signature |
|---|---|
| Cancer: | Bladder Cancer |
| Drug: | Tecentriq (atezolizumab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The prognostic and predictive implications of the 12-chemokine score in muslce invasive bladder cancer
Published date:
11/11/2020
Excerpt:
...the 12CK-High signature conferred a median overall survival benefit of almost 1 year in the atezolizumab-treated patient.In muslce invasive bladder cancer, 12CK-High scores corresponded with formation of TLS in the TME; favourable prognosis in surgically treated MIBC patients; and CR in atezolizumab-treated patients.
